Patents by Inventor Gordon Power

Gordon Power has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220144954
    Abstract: The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of making and using same. Methods of use include methods of treatment of cancer, including leukemias, lymphomas, solid tumors and melanomas.
    Type: Application
    Filed: November 18, 2021
    Publication date: May 12, 2022
    Inventors: Linda Snyder, Gordon Powers
  • Patent number: 11242392
    Abstract: The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of making and using same. Methods of use include methods of treatment of cancer, including leukemias, lymphomas, solid tumors and melanomas.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: February 8, 2022
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Linda Snyder, Gordon Powers
  • Publication number: 20210347896
    Abstract: The present invention relates to antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of eliciting certain biological responses using the antibodies. Compositions and methods of using anti-VISTA antibodies in combination with one or more antibodies that bind to immune checkpoint proteins are also provided.
    Type: Application
    Filed: May 20, 2021
    Publication date: November 11, 2021
    Inventors: Linda A. Snyder, Gordon Powers, Enrique Zudaire Ubani, Douglas Matthew Marvel
  • Publication number: 20210318322
    Abstract: The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of detecting VISTA.
    Type: Application
    Filed: March 18, 2021
    Publication date: October 14, 2021
    Inventors: Linda A. Snyder, Gordon Powers, Manuel Alejandro Sepulveda, John D. Alvarez
  • Publication number: 20210277110
    Abstract: The present invention relates to antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Application
    Filed: November 6, 2020
    Publication date: September 9, 2021
    Inventors: Raluca Verona, Gordon Powers, Nina Chi Sabins, Nikki A. DeAngelis, Sandra Santulli-Marotto, Karla R. Wiehagen, Sheng-Jiun Wu, Catherine Ferrante, Enrique Zudaire Ubani
  • Publication number: 20210171640
    Abstract: The present invention relates to antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of eliciting certain biological responses using the antibodies. Methods of identifying anti-VISTA antibodies capable of eliciting certain biological responses are also included.
    Type: Application
    Filed: November 25, 2020
    Publication date: June 10, 2021
    Inventors: Linda A. Snyder, Gordon Powers, Enrique Zudaire Ubani, Douglas Matthew Marvel
  • Patent number: 11014987
    Abstract: The present invention relates to antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of eliciting certain biological responses using the antibodies. Compositions and methods of using anti-VISTA antibodies in combination with one or more antibodies that bind to immune checkpoint proteins are also provided.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: May 25, 2021
    Assignee: Janssen Pharmaceutics NV
    Inventors: Linda A. Snyder, Gordon Powers, Enrique Zudaire Ubani, Douglas Matthew Marvel
  • Patent number: 11009509
    Abstract: The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of detecting VISTA.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: May 18, 2021
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Linda A. Snyder, Gordon Powers, Manuel Alejandro Sepulveda, John D. Alvarez
  • Patent number: 10899836
    Abstract: The present invention relates to antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of eliciting certain biological responses using the antibodies. Methods of identifying anti-VISTA antibodies capable of eliciting certain biological responses are also included.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: January 26, 2021
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Linda A. Snyder, Gordon Powers, Enrique Zudaire Ubani, Douglas Matthew Marvel
  • Patent number: 10894830
    Abstract: The present invention relates to antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Grant
    Filed: November 1, 2016
    Date of Patent: January 19, 2021
    Assignee: Janssen Biotech, Inc.
    Inventors: Raluca Verona, Gordon Powers, Nina Chi Sabins, Nikki A DeAngelis, Sandra Santulli-Marotto, Karla R Wiehagen, Sheng-Jiun Wu, Catherine Ferrante, Enrique Zudaire Ubani
  • Publication number: 20200017589
    Abstract: The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of making and using same. Methods of use include methods of treatment of cancer, including leukemias, lymphomas, solid tumors and melanomas.
    Type: Application
    Filed: April 26, 2019
    Publication date: January 16, 2020
    Inventors: Linda Snyder, Gordon Powers
  • Publication number: 20190330349
    Abstract: The invention provides antagonistic and agonistic anti-human VISTA antibodies and antibody fragments. These antagonist antibodies and antibody fragments may be used to inhibit or block VISTA's suppressive effects on T cell immunity and thereby promote T cell immunity. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These antagonist antibodies and antibody fragments are especially useful in the treatment of cancer and infectious conditions. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.
    Type: Application
    Filed: April 14, 2017
    Publication date: October 31, 2019
    Inventors: Michael MOLLOY, Jay ROTHSTEIN, Dov PECHENICK, Linda SNYDER, Gordon POWERS
  • Patent number: 10273301
    Abstract: The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of making and using same. Methods of use include methods of treatment of cancer, including leukemias, lymphomas, solid tumors and melanomas.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: April 30, 2019
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Linda Snyder, Gordon Powers
  • Publication number: 20180306799
    Abstract: The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of detecting VISTA.
    Type: Application
    Filed: June 23, 2016
    Publication date: October 25, 2018
    Applicant: Janssen Pharmaceutica NV
    Inventors: Linda A. Snyder, Gordon Powers, Manuel Alejandro Sepulveda, John D. Alvarez
  • Publication number: 20180079811
    Abstract: The invention provides antagonistic and agonistic anti-human VISTA antibodies and antibody fragments. These antagonist antibodies and antibody fragments may be used to inhibit or block VISTA's suppressive effects on T cell immunity and thereby promote T cell immunity. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These antagonist antibodies and antibody fragments are especially useful in the treatment of cancer and infectious conditions. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.
    Type: Application
    Filed: April 14, 2017
    Publication date: March 22, 2018
    Inventors: Michael MOLLOY, Jay ROTHSTEIN, Dov PECHENICK, Linda SNYDER, Gordon POWERS
  • Publication number: 20170320950
    Abstract: The present invention relates to antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of eliciting certain biological responses using the antibodies. Compositions and methods of using anti-VISTA antibodies in combination with one or more antibodies that bind to immune checkpoint proteins are also provided.
    Type: Application
    Filed: April 6, 2017
    Publication date: November 9, 2017
    Inventors: Linda A. Snyder, Gordon Powers, Enrique Zudaire Ubani, Douglas Matthew Marvel
  • Publication number: 20170233479
    Abstract: The present invention relates to antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of eliciting certain biological responses using the antibodies. Methods of identifying anti-VISTA antibodies capable of eliciting certain biological responses are also included.
    Type: Application
    Filed: February 10, 2017
    Publication date: August 17, 2017
    Inventors: Linda A. Snyder, Gordon Powers, Enrique Zudaire Ubani, Douglas Matthew Marvel
  • Publication number: 20170121409
    Abstract: The present invention relates to antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Application
    Filed: November 1, 2016
    Publication date: May 4, 2017
    Applicant: Janssen Biotech, Inc.
    Inventors: Raluca Verona, Gordon Powers, Nina Chi Sabins, Nikki A. DeAngelis, Sandra Santulli-Marotto, Karla R. Wiehagen
  • Publication number: 20170051061
    Abstract: The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of making and using same. Methods of use include methods of treatment of cancer, including leukemias, lymphomas, solid tumors and melanomas.
    Type: Application
    Filed: December 22, 2014
    Publication date: February 23, 2017
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Linda Snyder, Gordon Powers
  • Patent number: 8691864
    Abstract: The present invention provides compounds and methods of administering compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease ?APP production.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: April 8, 2014
    Inventors: Nigel H. Greig, Karen T. Y. Shaw, Qiang-Sheng Yu, Harold W. Holloway, Tada Utsuki, Timothy T. Soncrant, Donald K. Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane M. Davidson, Michael Sturgess